Editorial Simplified : Different Peas in Different Pods | GS – III


Relevance :  GS Paper  III


Theme of the article

Unlike IT, it would be a mistake to look at the biotechnology sector through the lens of employment generation only.


Why has this issue cropped up?

India is among the first countries to set up a specialised agency for the development of research and human resources in the biotechnology sector.


The status of biotechnology sector in India

  • Modern biotechnological research is expensive. It requires a highly trained and skilled workforce and access to expensive instruments.
  • So far, most of the high-quality research output has come from a handful of institutions with better scientific infrastructure. The rest, which forms the bulk of the research publications, is of mediocre quality.
  • Over the years, the focus of research has slowly shifted from fundamental to applied research.

Why has research in biotechnology sector not bore fruits in India?

  • The fruits of applied research will only come when we start investing in basic research without asking for quick returns.
  • While continuing and increasing the share of funding in basic research, the government should encourage and incentivise the private sector to invest substantially in applied research.
  • Compared to the developed economies (the United States), biotechnology research in India is mainly funded by the public exchequer. Unless the private sector starts supporting applied research and engages with academic institutions, the innovation in applied and translational biotechnology will be minimal.

Creation of human resources and jobs in biotechnology sector

  • In India, unlike the IT sector, a large pool of the English-speaking workforce, low wages of scientists (compared to the developed economies) and a sizeable institutional research base have not helped create more jobs in biotechnology.
  • There may be several possible reasons.
    • Biotechnology research often requires access to laboratories with high-end scientific infrastructure, the supply of expensive chemicals and reagents with minimum shipping time between the supplier and the user, and a disciplined work culture and documentation practice due to regulatory and intellectual property filing requirement.
    • Additionally, unlike the products and solutions from the IT industry, biotechnology products and solutions often require ethical and regulatory clearance, making the process long, expensive and cumbersome.
    • As the nature of the work in the biotechnology sector is specialised, most jobs are filled with experienced and skilled scientists leaving the demand for young and inexperienced ones low.

Comparison with China

  • Unlike India, China has many more labs with the best of scientific infrastructure; each with more number of skilled human resources trained in regimental work culture and trained to practise rigorous documentation.
  • Chinese students and scientists outnumber Indians nearly 5:1 in most American universities in the life sciences/biology-related disciplines.
  • A booming economy and a higher science budget coupled with a flexible hiring system have made Chinese universities and research labs attract many overseas

Not just an employment issue

  • The future of biotechnology is bright in India. However, the sector is not going to displace the IT sector anytime soon in employment generation.
  • Discoveries in biotechnology may help us solve some of the pressing societal issues of our time: cleaning our rivers, producing life-saving drugs, feeding our growing population with nutritious food and helping us clean the air we breathe.
  • Therefore, it will be a mistake to look at the biotechnology sector through the lens of employment generation only.

Way forward

  • Our government needs to make the process of hiring in our universities and national labs simpler and flexible, not necessarily provide more salary, to attract the bright overseas Indian scientists.
  • Unlike the IT sector, the biotechnology sector requires years of experience in the domain, access to labs with sophisticated instruments, sustained and long-term funding to innovate.
  • The government has been supporting biotech entrepreneurs. Initiatives through the Biotechnology Industry Research Assistance Council (BIRAC) of the Department of Biotechnology to support the innovation ecosystems have resulted in an impressive outcome.
  • Two successful hotbeds for biotech innovation, Boston and Silicon Valley in the U.S., may provide us some clues. Along with the availability of funding, infrastructure and skilled workforce, the presence of top-notch research institutions and universities in the vicinity make these two places among the most attractive locations for biotech start-up companies anywhere.
  • Unlike the IT and e-commerce space, ideas for biotechnology companies are initiated in scientific research labs while their parent academic institutions work as feeders of intellectual property. Therefore, unlike the IT sector, a sustained innovation and product development model in the biotechnology field without enriching the academic institutions is not possible.
  • The government is very encouraging and promoting entrepreneurship, but the culture of institutions and scientists to be entrepreneurial will take time. This will require a flexible policy in the institutes to allow scientists incubate start-up companies in their labs while retaining their positions.
  • The government should let scientists from research institutions and universities take unpaid leave to join the industry for a fixed period. Similarly, the government should relax rules to appoint researchers from industry in faculty positions with the freedom to teach, participate, and take students.
  • Without a sustained effort in encouraging and promoting science-driven innovation in our academic institutions, and a robust academia-industry collaboration, biotechnology-led innovation will not aid the nation’s economic growth.
  • The use of artificial intelligence-based tools and applications of big data in biology will leverage India’s strength in IT and move biotech innovations faster to the marketplace

 

Leave a Reply